In a meta-analysis comparing GnRH-a versus GnRH-ant for controlled ovarian stimulation in oocyte donors, Bodri et al. found no significant difference in the incidence of OHSS by comparing protocols with GnRH agonists versus antagonists[RR 0.61(95%) CI 0.18 to 2.15, P = 45, heterogeneity P = 45, I2 0% fixed effects model] [14]. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.